Biocryst Pharmaceuticals, Inc. splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was ORLADEYO at $601.8 million, 69% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
962
|
875
|
451
|
331
|
271
|
157
|
18
|
49
|
21
|
25
|
26
|
| ORLADEYO |
—
|
602
+37.5%
share 68.8%
|
438
+34.3%
share 97.1%
|
326
+29.5%
share 98.4%
|
252
+105.3%
share 92.9%
|
123
share 78.0%
|
—
|
—
|
—
|
—
|
—
|
| License |
—
|
244
share 27.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| License Revenue And Other Income From Contract With Customer |
—
|
29
+122.3%
share 3.3%
|
13
+140.7%
share 2.9%
|
5
-71.8%
share 1.6%
|
19
-44.6%
share 7.1%
|
35
share 22.0%
|
—
|
—
|
—
|
—
|
—
|
| Milestone |
—
|
—
|
—
|
—
|
—
|
15
share 9.5%
|
—
|
—
|
—
|
—
|
—
|
| License And Other Revenues |
—
|
—
|
8
+19.8%
share 1.8%
|
7
share 2.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaborative And Other Research And Development |
—
|
8
-4.2%
share 0.9%
|
8
+19.8%
share 1.8%
|
7
+115.5%
share 2.0%
|
3
-85.0%
share 1.2%
|
21
+87.1%
share 13.2%
|
11
-55.5%
share 62.5%
|
25
share 51.2%
|
—
|
—
|
—
|
| Royalty |
—
|
—
|
—
|
—
|
—
|
-0
-103.0%
share -0.1%
|
3
-46.4%
share 19.0%
|
6
share 12.9%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.